SNCA antisense oligonucleotide therapy (Osaka University)

N/A

Report date: 2025/01/26 16:59:17

NME

Base Information

Drug NameSNCA antisense oligonucleotide therapy (Osaka University)

Drug Alias Nameamido-bridged nucleic acids-modified SNCA antisense oligonucleotide therapy (intracerebroventricular, Parkinson’s disease) (Osaka University)

ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense

Mechanisms of ActionSynuclein alpha inhibitors

TargetsSynuclein alpha

Therapy Area/IndicationsParkinson Disease

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryJapan

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesOsaka University

China Registration ClassN/A

Develop Information

Active CompaniesOsaka University

Inactive CompaniesN/A

Active IndicationsParkinson Disease

Inactive IndicationsN/A

Other Information

ATC CodeN/A